Envestnet Portfolio Solutions
BIO icon

Envestnet Portfolio Solutions’s Bio-Rad Laboratories Class A BIO Stock Holding History

Envestnet Portfolio Solutions’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Buy
2,670
+841
+46% +$239K ﹤0.01% 805
2026
Q1 		$510K Buy
1,829
+1,141
+166% +$329K ﹤0.01% 892
2025
Q4 		$208K Sell
688
-125
-15% -$39K ﹤0.01% 1447
2025
Q3 		$228K Sell
813
-165
-17% -$44.9K ﹤0.01% 1374
2025
Q2 		$236K Sell
978
-315
-24% -$74.5K ﹤0.01% 1439
2025
Q1 		$315K Sell
1,293
-801
-38% -$241K ﹤0.01% 1265
2024
Q4 		$688K Buy
2,094
+388
+23% +$132K ﹤0.01% 1087
2024
Q3 		$571K Buy
1,706
+75
+5% +$23.8K ﹤0.01% 1130
2024
Q2 		$445K Buy
1,631
+7
+0.4% +$2.04K ﹤0.01% 1191
2024
Q1 		$562K Sell
1,624
-927
-36% -$305K ﹤0.01% 1073
2023
Q4 		$824K Sell
2,551
-2,559
-50% -$802K ﹤0.01% 849
2023
Q3 		$1.83M Buy
+5,110
New +$1.97M 0.01% 564

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Envestnet Portfolio Solutions's BIO Position: Q2 2026 in Review

Envestnet Portfolio Solutions increased its Bio-Rad Laboratories Class A (BIO) stake by 46% in Q2 2026, buying an estimated $239K and bringing the position to 2,670 shares worth $784K. The position accounts for ﹤0.01% of the portfolio, ranked #805.

Envestnet Portfolio Solutions first reported a position in BIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.83M in Q3 2023. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Envestnet Portfolio Solutions held 2,670 shares of Bio-Rad Laboratories Class A worth $784K as of Q2 2026.
  • Envestnet Portfolio Solutions bought 841 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $239K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q2 2026, its #805 holding.
  • Envestnet Portfolio Solutions first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and has held it in 12 quarters since.
  • Envestnet Portfolio Solutions's Bio-Rad Laboratories Class A position peaked at $1.83M in Q3 2023.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2026, filed 20 Jul 2026.